The EU’s Court of Justice has sided with European regulators and a number of member states in agreeing that Aplidin (plitidepsin), a cancer drug from Spain’s PharmaMar, should not be approved for marketing in the EU.
The court set aside an earlier judgment by the General Court that said the European Commission’s decision to reject the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?